pharma · Colitis, Ulcerative · Multiple Myeloma
Janssen Cilag International
Janssen Cilag International NV
Janssen-Cilag Farmaceutica Ltda is a pharma organization headquartered in São Paulo, EU. Primary therapeutic focus areas include Colitis, Ulcerative, Multiple Myeloma, Diabetes Mellitus, Type 2, Depressive Disorder, Majo
São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- São Paulo, EU
- Employees
- 13
- Programs
- 46
- Drugs
- 37
- Patents
- 0
Ustekinumab Dose Based on BSA and Body Weight
Phase 3 · small molecule · Colitis, Ulcerative
Ustekinumab Dose Based on BSA and Body Weight for Colitis, Ulcerative is a Phase 3 program (small_molecule) at Janssen Cilag International NV with 1 ClinicalTrials.gov record(s).
Internal code CR108865
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Janssen Cilag International NV
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Colitis, Ulcerative
- Status
- completed
- Trials
- 1